← The Wire·Regulation··2 outlets

FDA extends review of Exelixis drug candidate zanzalintinib, delaying decision

Exelixis shares fell after the FDA extended its review of zanzalintinib, delaying a regulatory decision on the company’s key drug candidate. The move shifts near-term attention to the revised review timeline and the drug’s eventual approval outcome.

STOCK PHOTO · PIXABAY

The story

Investing.com reported that Exelixis stock fell after the FDA extended its review of zanzalintinib.

Zanzalintinib is now the immediate regulatory focus for Exelixis, while the company’s most recently cited annual figures show $2.3B in revenue, up 7.0% year over year, and a 33.7% net margin with $2.78 in diluted EPS. Those figures describe the fiscal year ended 2026-01-02 and do not establish how the review extension will affect future results.

The direct mechanism is regulatory: a longer FDA review postpones clarity on the candidate’s approval status and any associated commercial contribution.

The stock reaction indicates that the extension was negative for the shares. The key open item is the FDA’s revised action date and any explanation from Exelixis or the agency.

Future coverage should focus on the new FDA decision date, company comments on the reason for the extension, and the eventual regulatory action. Until those details are disclosed, the size and persistence of the commercial impact remain uncertain.

Our read · Fri, Sep 11

The FDA review extension moves the near-term risk to the downside for EXEL, with the catalyst timeline and approval path now less clear.

Why. The delay removes a near-term regulatory catalyst and leaves the market without a disclosed explanation for the extension, making timing risk the immediate pressure point for EXEL. The company has a substantial existing business, with $2.3B of annual revenue and a 33.7% net margin.

Both cases

The case it holdsExelixis already reports $2.3B in annual revenue and a 33.7% net margin.
The case it breaksThe extension delays regulatory clarity and could signal additional FDA questions, but Investing.com disclosed neither a new action date nor the reason for the review change.

What could change this view: A prompt FDA explanation confirming a routine administrative extension, followed by approval, would remove the central concern and reverse the delay-driven pressure.

Exelixis stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 2

Investing.comoriginalFri, Sep 11 · 8:52 AM ETExelixis stock falls as FDA extends zanzalintinib review

Keep reading

Latest on the Wire

Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Investing.com as Exelixis stock falls as FDA extends zanzalintinib review, . Who answers for this

2 reports from 2 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →